However, considering the general failure to treat human muscle diseases so far, a more specific myostatin inhibition may be required that decreases or eliminates the effect on other molecular pathways related to myostatin signaling for the continued relevance in muscle atrophy diseases. The gene discussed is MSTN; the disease is muscle atrophy.